Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF4113 in Metastatic Prostate Cancer
NCT07636707Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Jan 2028
01
Overview
Phase 1, open-label, single-arm trial of QLF4113 in castration-resistant prostate cancer (CRPC), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 21 days, Maximum Administered Dose at 21 days and 4 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
QLF4113
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07636707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636707.